 Dulcy Wolverton
Concepts (78)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 11 | 2023 | 1965 | 0.480 |
Why?
| | Mammography | 6 | 2020 | 126 | 0.410 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 3 | 2017 | 58 | 0.310 |
Why?
| | Communication | 2 | 2023 | 761 | 0.290 |
Why?
| | Chemotherapy, Adjuvant | 3 | 2021 | 360 | 0.230 |
Why?
| | Patients | 1 | 2023 | 175 | 0.210 |
Why?
| | Image Enhancement | 2 | 2021 | 181 | 0.200 |
Why?
| | Neoadjuvant Therapy | 2 | 2021 | 333 | 0.190 |
Why?
| | Mastectomy | 2 | 2020 | 124 | 0.190 |
Why?
| | Comprehension | 1 | 2022 | 163 | 0.190 |
Why?
| | Magnetic Resonance Imaging | 5 | 2021 | 3175 | 0.180 |
Why?
| | Contrast Media | 2 | 2021 | 373 | 0.180 |
Why?
| | Health Literacy | 1 | 2022 | 169 | 0.180 |
Why?
| | Delayed Diagnosis | 1 | 2020 | 79 | 0.180 |
Why?
| | Early Detection of Cancer | 1 | 2023 | 360 | 0.170 |
Why?
| | Radiology | 1 | 2021 | 199 | 0.160 |
Why?
| | Aromatase Inhibitors | 1 | 2017 | 52 | 0.150 |
Why?
| | Patient Care Management | 1 | 2017 | 57 | 0.150 |
Why?
| | Breast | 2 | 2021 | 140 | 0.110 |
Why?
| | Receptors, Estrogen | 1 | 2011 | 387 | 0.080 |
Why?
| | Fibroadenoma | 1 | 2005 | 2 | 0.070 |
Why?
| | Phyllodes Tumor | 1 | 2005 | 2 | 0.070 |
Why?
| | Carcinoma, Ductal | 1 | 2005 | 12 | 0.070 |
Why?
| | Spectrum Analysis | 1 | 2005 | 88 | 0.060 |
Why?
| | Neoplasms | 1 | 2018 | 2179 | 0.060 |
Why?
| | Humans | 16 | 2023 | 119032 | 0.060 |
Why?
| | Aged | 6 | 2021 | 19661 | 0.050 |
Why?
| | Female | 11 | 2023 | 61588 | 0.050 |
Why?
| | Medical Oncology | 1 | 2023 | 229 | 0.050 |
Why?
| | Electronics | 1 | 2021 | 76 | 0.050 |
Why?
| | Neoplasm Staging | 3 | 2017 | 1223 | 0.050 |
Why?
| | Middle Aged | 7 | 2021 | 27627 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 4709 | 0.050 |
Why?
| | Educational Status | 1 | 2022 | 437 | 0.050 |
Why?
| | Family Practice | 1 | 2023 | 438 | 0.040 |
Why?
| | Qualitative Research | 1 | 2023 | 953 | 0.040 |
Why?
| | Health Personnel | 1 | 2023 | 588 | 0.040 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2005 | 1390 | 0.040 |
Why?
| | Cohort Studies | 2 | 2021 | 5117 | 0.040 |
Why?
| | Patient-Centered Care | 1 | 2022 | 497 | 0.040 |
Why?
| | Referral and Consultation | 1 | 2021 | 648 | 0.040 |
Why?
| | Neoplasm Grading | 1 | 2017 | 258 | 0.040 |
Why?
| | Breast Diseases | 1 | 1996 | 20 | 0.040 |
Why?
| | Treatment Outcome | 3 | 2021 | 9346 | 0.030 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 1996 | 109 | 0.030 |
Why?
| | Adult | 5 | 2021 | 31525 | 0.030 |
Why?
| | Medicare | 1 | 2020 | 665 | 0.030 |
Why?
| | Prognosis | 2 | 2017 | 3443 | 0.030 |
Why?
| | Software | 1 | 2018 | 613 | 0.030 |
Why?
| | Biopsy | 1 | 2017 | 1079 | 0.030 |
Why?
| | Mass Screening | 1 | 2000 | 1052 | 0.030 |
Why?
| | Calcinosis | 1 | 1996 | 282 | 0.030 |
Why?
| | Databases, Factual | 1 | 2018 | 1231 | 0.030 |
Why?
| | Biopsy, Needle | 2 | 2005 | 190 | 0.030 |
Why?
| | Immunohistochemistry | 2 | 2006 | 1691 | 0.030 |
Why?
| | Aged, 80 and over | 2 | 2005 | 6562 | 0.020 |
Why?
| | Retrospective Studies | 2 | 2021 | 12990 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 2011 | 1167 | 0.020 |
Why?
| | Sensitivity and Specificity | 2 | 2005 | 1795 | 0.020 |
Why?
| | Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 55 | 0.020 |
Why?
| | Antigens, CD34 | 1 | 2006 | 98 | 0.020 |
Why?
| | Ki-67 Antigen | 1 | 2006 | 108 | 0.020 |
Why?
| | Young Adult | 1 | 2021 | 10799 | 0.020 |
Why?
| | Subtraction Technique | 1 | 2005 | 27 | 0.020 |
Why?
| | Gadolinium DTPA | 1 | 2005 | 54 | 0.020 |
Why?
| | Lasers | 1 | 2005 | 124 | 0.020 |
Why?
| | Prospective Studies | 1 | 1996 | 6477 | 0.020 |
Why?
| | Diagnosis, Differential | 2 | 2000 | 1384 | 0.020 |
Why?
| | Antigens, CD | 1 | 2006 | 460 | 0.010 |
Why?
| | Radiography | 1 | 2006 | 861 | 0.010 |
Why?
| | United States | 1 | 2020 | 12557 | 0.010 |
Why?
| | Follow-Up Studies | 1 | 2011 | 4596 | 0.010 |
Why?
| | Biomarkers, Tumor | 1 | 2006 | 1059 | 0.010 |
Why?
| | Physical Examination | 1 | 2000 | 243 | 0.010 |
Why?
| | Reproducibility of Results | 1 | 2005 | 2874 | 0.010 |
Why?
| | Inflammation | 1 | 2006 | 2571 | 0.010 |
Why?
| | ROC Curve | 1 | 1996 | 473 | 0.010 |
Why?
| | Adolescent | 1 | 2005 | 18483 | 0.000 |
Why?
|
|
Wolverton's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|